7702.T
Toshiba provides medical equipment, supplies, and distribution services, generating revenue primarily through the sale and servicing of diagnostic imaging systems, medical devices, and related healthcare solutions.
Business. Toshiba provides medical equipment, supplies, and distribution services, generating revenue primarily through the sale and servicing of diagnostic imaging systems, medical devices, and related healthcare solutions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Toshiba provides medical equipment, supplies, and distribution services, generating revenue primarily through the sale and servicing of diagnostic imaging systems, medical devices, and related healthcare solutions.
Toshiba maintains a capital structure with a debt-to-equity ratio of 0.6, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.79, suggesting it can cover its short-term obligations with its current assets. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.
Profitability metrics for Toshiba are below typical industry benchmarks. The company's return on equity (ROE) is 0.0022, and its return on assets (ROA) is 0.0011, both of which are significantly lower than the median for the Medical Equipment, Supplies & Distribution industry. This suggests that the company is underperforming in terms of generating returns from its equity and asset base.
Toshiba's revenue is primarily concentrated in the healthcare services and equipment segment, with a significant portion derived from domestic operations in Japan. The company's geographic exposure is limited, with a high concentration of revenue in its home market, which may increase its vulnerability to local economic conditions.
The company's growth trajectory appears to be modest. Based on the outlook data, Toshiba is expected to see a slight increase in revenue in the current fiscal year, but the magnitude of the growth is not specified. Historical revenue data indicates a stable but not rapidly growing business, with the most recent reported revenue at 69.75 billion JPY.
Risk factors for Toshiba include a medium liquidity risk, as indicated by the negative net cash position after subtracting total debt. The company's dilution potential is assessed as low, suggesting that there is little immediate threat to shareholder value from new share issuances. However, the company's capital structure and liquidity position may require close monitoring in the near term.
Recent events and filings have not indicated any major changes in the company's strategic direction or financial health. The latest analyst estimates align with the reported financial results, with the last actual EPS at 3.65 JPY and revenue at 69.75 billion JPY. These figures suggest that the company is meeting or slightly exceeding analyst expectations, but there is no indication of significant outperformance.
- Toshiba's debt-to-equity ratio of 0.6 indicates a moderate level of debt financing.
- The company's ROE and ROA are below industry medians, suggesting underperformance in profitability.
- Revenue is heavily concentrated in the healthcare services and equipment segment and domestic operations in Japan.
- Growth is expected to be modest, with no significant revenue increases forecasted.
- The company faces medium liquidity risk and a low dilution potential.
- Analyst estimates are in line with reported financial results, indicating stable performance.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 7702.T Market data — financials · 2026-05-27
- JMS Co Ltd Market data — analyst estimates · 2026-05-27